Citation Impact
Citing Papers
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
2011
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement
2012
Evolution of the Cancer Stem Cell Model
2014 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation
2015
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
2013
Targeted glycan degradation potentiates the anticancer immune response in vivo
2020 StandoutNobel
Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets
2015
Cancer treatment and survivorship statistics, 2022
2022 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
2015
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
2014 Standout
Antibody–Drug Conjugate Payloads
2013
The prevalence and clinical significance of 18F–2‐fluoro‐2‐deoxy‐D‐glucose (FDG) uptake in the thyroid gland on PET or PET‐CT in patients with lymphoma
2010
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
2013
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Acute lymphoblastic leukaemia
2013
Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies
2013
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
2012
Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery
2021 StandoutNobel
Relapsed childhood acute lymphoblastic leukaemia
2013
Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
2012
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
2014
Anaplastic Thyroid Carcinoma, Thyroid Lymphoma, and Metastasis to Thyroid
2006
Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches
2015
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
2013 Standout
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing
2015
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists
2010
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Pyroptosis: A new frontier in cancer
2019 Standout
In utero nanoparticle delivery for site-specific genome editing
2018
The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer
2014
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
2020 Standout
Proteins related to the spindle and checkpoint mitotic emphasize the different pathogenesis of hypoplastic MDS
2013
Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?
2012
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
2019 StandoutNobel
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
2014
Donor HLA-specific Abs: to BMT or not to BMT?
2015
EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
2011
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities
2017
Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC
2014
Acute Myeloid Leukemia
2015 Standout
The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
2013
Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a M ayo C linic‐F rench C onsortium S tudy
2014
Desensitization for solid organ and hematopoietic stem cell transplantation
2014
Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?
2012
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
2016
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns
2010
Chimeric Antigen Receptor Therapy
2018 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders
2012
Inhibitors of the anaplastic lymphoma kinase
2012
A perspective on the selection of unrelated donors and cord blood units for transplantation
2012
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Antibody-Drug Conjugates in Cancer Therapy
2012
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
2015
Cancer treatment and survivorship statistics, 2019
2019 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Formylglycine, a Post-Translationally Generated Residue with Unique Catalytic Capabilities and Biotechnology Applications
2014 StandoutNobel
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
Anaplastic lymphoma kinase: signalling in development and disease
2009
Guidelines for the management of thyroid cancer
2014 Standout
CAR T cell immunotherapy for human cancer
2018 StandoutScience
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Linkers Having a Crucial Role in Antibody–Drug Conjugates
2016
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?
2016
Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?
2012
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Sa A. Wang being referenced
Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation
2011
Anaplastic lymphoma kinase–positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3′ ALK gene insertion to chromosome 4 q22-24
2007
High‐grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis
2012
Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature
2005
The Oncofetal Protein IMP3: A Novel Molecular Marker to Predict Aggressive Meningioma
2011
Low Histologic Grade Follicular Lymphoma With High Proliferation Index
2005
Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome
2007
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
2012
The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a “basal-like” subset?
2008
Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vβ chain antibodies and its application in blood staging
2009
Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML
2012
Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification
2010
Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics
2015
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification
2009
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution
2014
Clinicopathologic Features of CD5-Positive Nodal Marginal Zone Lymphoma
2013
Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome
2009
Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma
2012
Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
2013